# Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

> **NCT07521046** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Utah** · enrollment: 15 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** ropeginterferon alfa- 2b
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT07521046
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-05
- **Final completion:** 2030-05
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07521046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07521046, "Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07521046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*